10-Ethyl-2,3-dihydro-1H-3a-aza-10-azonia-pentaleno[1,2-b]naphthalene; iodide | 59504-79-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 10-Ethyl-2,3-dihydro-1H-3a-aza-10-azonia-pentaleno[1,2-b]naphthalene; iodide
• 英文别名: 16-Ethyl-16-aza-11-azoniatetracyclo[8.6.0.03,8.011,15]hexadeca-1,3,5,7,9,11(15)-hexaene;iodide
• CAS: 59504-79-9
• 化学式: C₁₆H₁₇N₂*I
• 分子量: 364.229
• InChiKey: MWPAKLIQZWGTSO-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  0.05
• 重原子数：
  19.0
• 可旋转键数：
  1.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  8.81
• 氢给体数：
  0.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  2-(2-acetanilidovinyl)-1,3,3-trimethyl-3H-indolium iodide 、 10-Ethyl-2,3-dihydro-1H-3a-aza-10-azonia-pentaleno[1,2-b]naphthalene; iodide 在 吡啶 、 三乙胺 作用下， 以44%的产率得到10-Ethyl-1-[2-[1,3,3-trimethyl-1,3-dihydro-indol-(2E)-ylidene]-eth-(E)-ylidene]-1,2,3,10-tetrahydro-10-aza-3a-azonia-pentaleno[1,2-b]naphthalene; iodide
  参考文献：
  名称：

  Synthesis and substance P antagonist activity of naphthimidazolium derivatives

  摘要：

  The synthesis of unsymmetrical naphth[2,3-d]imidazolium and bridged naphth[2,3-d]imidazolium derivatives and their substance P (SP) antagonist activity are described. All compounds were evaluated for their ability to displace SP from neurokinin-1 (NK-1) receptor sites using standard receptor binding methodology (rat forebrain membrane). 1,3-Diethyl-2-[3-(1,3-dihydro-1,3,3-trimethyl-2H-indol-2-ylidene)-1-propenyl]-1H-naphth[2,3-d]imidazolium chloride (7a), a representative compound in this series, was further evaluated for SP antagonist activity in a guinea pig ileum contractility assay. In vivo SP antagonist activity of 7a was demonstrated using SP-induced salivation and paw edema models performed in rats.

  DOI：

  10.1021/jm00085a015
• 作为产物：
  描述：

  2,3-二氨基萘 、 alkaline earth salt of/the/ methylsulfuric acid 生成 10-Ethyl-2,3-dihydro-1H-3a-aza-10-azonia-pentaleno[1,2-b]naphthalene; iodide
  参考文献：
  名称：

  Synthesis and substance P antagonist activity of naphthimidazolium derivatives

  摘要：

  The synthesis of unsymmetrical naphth[2,3-d]imidazolium and bridged naphth[2,3-d]imidazolium derivatives and their substance P (SP) antagonist activity are described. All compounds were evaluated for their ability to displace SP from neurokinin-1 (NK-1) receptor sites using standard receptor binding methodology (rat forebrain membrane). 1,3-Diethyl-2-[3-(1,3-dihydro-1,3,3-trimethyl-2H-indol-2-ylidene)-1-propenyl]-1H-naphth[2,3-d]imidazolium chloride (7a), a representative compound in this series, was further evaluated for SP antagonist activity in a guinea pig ileum contractility assay. In vivo SP antagonist activity of 7a was demonstrated using SP-induced salivation and paw edema models performed in rats.

  DOI：

  10.1021/jm00085a015